跳转至内容
Merck
CN

T6394

Sigma-Aldrich

噻吗洛尔 马来酸盐

≥98% (TLC), β-adrenoceptor antagonist, powder

别名:

(S)-3-[3-(叔丁基氨基)-2-羟基丙氧基]-4-吗啉基-1,2,5-噻二唑马来酸盐 马来酸盐, (S)-马来酸噻吗洛尔

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C13H24N4O3S · C4H4O4
化学文摘社编号:
26921-17-5
分子量:
432.49
EC 号:
248-111-5
MDL编号:
MFCD00058356
UNSPSC代码:
12352200
PubChem化学物质编号:
24277810
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

噻吗洛尔 马来酸盐, ≥98% (TLC), powder

方案

≥98% (TLC)

表单

powder

旋光性

[α]25/D -5.4°, c = 4.9 in 1 M HCl(lit.)

颜色

white to off-white

mp

202-203 °C (lit.)

溶解性

H2O: soluble
ethanol: soluble

ε (消光系数)

8,700 at 294 nm at 1 M

创始人

Merck & Co., Inc., Kenilworth, NJ, U.S.

SMILES字符串

[H]\C(=C(/[H])C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2

InChI

1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1

InChI key

WLRMANUAADYWEA-NWASOUNVSA-N

基因信息

human ... ADRB1(153), ADRB2(154), ADRB3(155)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

Timolol maleate has been used as an adrenergic β-blocker for evaluating cardiovascular functions in mice5. It has also been used for evaluating the uptake of 86Rb+ in rat cardiomyocytes6.

生化/生理作用

Timolol maleate is a class II anti-arrhythmic agent that functions as a non-selective β-adrenoceptor antagonist, a vasodilator and an anti-glaucoma agent. Studies have reported that timolol maleate can be used for the treatment of infantile hemangioma (IH)7.

特点和优势

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

制备说明

Timolol maleate is soluble in ethanol and water.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Warning

危险声明

H302,H361

危险分类

Acute Tox. 4 Oral - Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

个人防护装备

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLBC3834V
061K1290
045H1255
045H1254
073H0074

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

G C Chiou et al.
Journal of ocular pharmacology, 8(3), 183-190 (1992-01-01)
An ocular hypertensive rabbit eye model was used to study the effect of L- and D-timolol on retinal and choroidal blood flow. Ocular hypertension was induced artificially by raising the intraocular pressure to 40 mmHg which reduced the ocular blood
Ajith Chakkittakandiyil et al.
Pediatric dermatology, 29(1), 28-31 (2011-12-14)
Therapeutic options for superficial infantile hemangiomas (IH) are limited. Recently, timolol maleate gel, a topical nonselective beta-blocker, has been reported as a potentially effective treatment for superficial IH. This study is an extension of a previously published pilot study designed
Verena Prokosch et al.
PloS one, 8(2), e49730-e49730 (2013-03-08)
Optic nerve atrophy caused by abnormal intraocular pressure (IOP) remains the most common cause of irreversible loss of vision worldwide. The aim of this study was to determine whether topically applied IOP-lowering eye drugs affect retinal ganglion cells (RGCs) and
A Tomidokoro et al.
Current eye research, 18(5), 381-390 (1999-06-18)
To evaluate the effects of topical carteolol or timolol on tissue circulation in the iris and posterior choroid. After a topical instillation of 20 microl of 2% carteolol, 0.5% timolol, or physiological saline (for control) into one eye, and physiological
Jin-Wei Cheng et al.
PloS one, 7(9), e45079-e45079 (2012-10-03)
The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), and the fixed-combination medications are needed to achieve sufficiently low target IOP. The aim of this systematic review and meta-analysis is to evaluate IOP-lowering effect of
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持